Journal article
Patient-reported outcomes of the Treatment and Prevention Study: A real-world community-based trial of direct-acting antivirals for hepatitis C among people who inject drugs
S Goutzamanis, T Spelman, B Harney, P Dietze, M Stoove, P Higgs, A Thompson, JS Doyle, M Hellard
Journal of Viral Hepatitis | WILEY | Published : 2021
DOI: 10.1111/jvh.13516
Abstract
The impact of hepatitis C cure with direct-acting antivirals (DAAs) on patient-reported outcomes (PROs) in community settings remains unclear. We aimed to assess changes in PROs over time and whether treatment was associated with sustained improved PROs in a cohort of people who inject drugs. This study is a sub-analysis of the Treatment and Prevention Study, a nurse-led trial where people who inject drugs and their injecting partners were recruited in a community setting, in Melbourne, Australia. Three participant groups were characterized: treatment, untreated and non-viremic (hepatitis C RNA negative at screening). PROs included assessment of health-related quality of life using the Short..
View full abstractGrants
Funding Acknowledgements
The Treatment and Prevention Study was supported by an investigator-initiated grant to the Burnet Institute from Gilead Sciences. PD is funded by a National Health and Medical Research Council (NHMRC) Senior Research Fellowship. The authors also acknowledge the contribution to this work of the Victorian Operational Infrastructure Support Program received by the Burnet Institute.